# Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer

> **NCT04460430** · PHASE2 · TERMINATED · sponsor: **SOLTI Breast Cancer Research Group** · enrollment: 12 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Neratinib + endocrine therapy

## Key facts

- **NCT ID:** NCT04460430
- **Lead sponsor:** SOLTI Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-23
- **Primary completion:** 2021-11-29
- **Final completion:** 2021-11-29
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** premature termination due to lack of funding
- **Last updated:** 2022-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04460430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04460430, "Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04460430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*